Cancer cells with mutated TP53 have accelerated tumor growth associated with increased VEGF expression and neovascularization [27], which represents an important survival pathway [7, 8], resulting in a therapeutic advantage of anti-angiogenesis inhibitors in TP53 mutant cancer patients [28]. The gene discussed is TP53; the disease is neoplasm.